InjectionGLP-1 + GIP
Tirzepatide + B12
A weekly dual-action GLP-1/GIP injection for meaningful weight loss and appetite control, paired with vitamin B12 for energy.
$208/mo on the 6-month plan
Medical weight loss, made simple.
Doctor-guided weight loss, personalized to your goals and shipped discreetly to your door.
Get StartedEvery weight loss medicine, in one place.
InjectionGLP-1
Semaglutide + B12
A weekly GLP-1 injection that quiets cravings and supports steady, sustainable weight loss, paired with vitamin B12 for energy.
Starting at $129/mo
Dissolving tabletGLP-1 + GIP
Tirzepatide ODT
Tirzepatide oral dissolving tablet. Dual GIP/GLP-1 agonist for weight loss. Escalating dose titration protocol.
Starting at $289/mo
Dissolving tabletGLP-1
Semaglutide ODT
Semaglutide oral dissolving tablet for weight loss. GLP-1 receptor agonist in sublingual form. Escalating dose titration.
Starting at $219/mo
Capsule
Phentermine / Topiramate
Combination of phentermine (stimulant) and topiramate (anticonvulsant) for weight loss. Controlled schedule III/V. Requires video visit.
Starting at $129/mo
Tablet
Metformin
Metformin commercial tablet for weight loss support and glucose metabolism. Take daily, 30-day supply.
Starting at $69/mo
Capsule
Naltrexone (Low Dose)
Low-dose naltrexone for weight loss, appetite control, and inflammation support. Off-label use. Daily capsule.
Starting at $69/mo
See all 18 weight loss treatments
Prices from our live catalog. Longer plans cost less per month.
Side effects
Contact your provider immediately if you have severe stomach pain that does not go away (possible pancreatitis); a lump or swelling in your neck, hoarseness, or trouble swallowing (possible thyroid tumor); severe vomiting or diarrhea with signs of dehydration; symptoms of low blood sugar; or signs of a serious allergic reaction. Regular check-ins help your physician follow your response to treatment.
Common side effects may include:
Nausea; diarrhea; vomiting; constipation; stomach pain; indigestion; injection-site reactions; tiredness; burping; hair loss; heartburn.
Rare, but serious side effects may include:
- Pancreatitis
- Gallbladder problems, including gallstones
- Kidney problems, usually from dehydration
- Severe stomach and bowel problems
- Low blood sugar, especially with insulin or sulfonylureas
- Serious allergic reactions
- Food or liquid getting into the lungs during anesthesia or deep sedation
- Depression or thoughts of suicide (tell your physician)
- Eye problems in people with type 2 diabetes and retinopathy
- Thyroid C-cell tumors in rodents: not for anyone with a personal or family history of medullary thyroid cancer or MEN 2
Nearly 74% of adults in the U.S. have overweight or obesity.
Adjust the scale to see the average one-year loss in the trials.
Your current weight (lbs):
270
In one year the average was (lbs):
41
Uses the roughly 15% mean weight loss over about a year in the brand-name trials (STEP 1, semaglutide 2.4 mg: 14.9% at 68 weeks; SURMOUNT-1, tirzepatide 15 mg: 20.9% at 72 weeks), with diet and exercise. A study average, not a prediction of your result; compounded versions were not studied in these trials. Adult figure: CDC, NHANES 2017–2018.
Semaglutide vs tirzepatide
Two proven medicines. Different ways of working.
GLP-1
Semaglutide
Weekly injection or daily dissolving tablet
- How it works: Activates the GLP-1 receptor to curb appetite and slow digestion.
- In the trials: 14.9% average weight loss at 68 weeks with brand-name 2.4 mg (STEP 1).
- Dosing: Once a week under the skin, or one tablet under the tongue each day.
- Cost: From $129/mo, out of pocket. Longer plans cost less per month.
GLP-1 + GIP
Tirzepatide
Weekly injection or daily dissolving tablet
- How it works: Activates both the GLP-1 and GIP receptors, two hormones that regulate appetite.
- In the trials: 20.9% average weight loss at 72 weeks with brand-name 15 mg (SURMOUNT-1).
- Dosing: Once a week under the skin, or one tablet under the tongue each day.
- Cost: From $208/mo, out of pocket. Longer plans cost less per month.
Both are prescribed and followed by a licensed physician, and you can switch as your needs change.
Compounded medications are not FDA-approved for safety, efficacy, or quality.
Protect your long-term health
GLP-1 medicines act on the gut hormones that regulate appetite, blood sugar and how full you feel after eating, supporting weight loss alongside diet and physical activity.
Excess weight raises the risk of
Type 2 diabetes
In people with prediabetes, losing about 7% of body weight cut the risk of type 2 diabetes by 58%.
Excess weight is tied to
Heart disease
In adults with heart disease and overweight, semaglutide lowered major heart events by 20%.
Excess weight is linked to
Certain cancers
Overweight and obesity are associated with at least 13 types of cancer.
It's easy to get started.
01
Complete your evaluation
Answer a few health questions online. No appointment needed, no waiting rooms.
02
Physician review
A U.S.-licensed physician reviews your information and decides whether a GLP-1 is right for you.
03
Treatment delivered
If prescribed, your medication ships to your door in discreet packaging.
Weight Loss Treatment FAQs
Contact supportWhat is medical weight loss?
Weight loss treatment prescribed and followed by a physician: here, GLP-1 medicines such as tirzepatide and semaglutide, alongside diet and activity. A U.S.-licensed physician reviews your health, prescribes only if it fits and adjusts the dose with you.
Is compounded tirzepatide the same as Zepbound?
Both contain tirzepatide, but they are different products. Zepbound® is FDA-approved and made by Eli Lilly; compounded tirzepatide is prepared by a licensed U.S. pharmacy under your prescription and is not FDA-approved. We don't offer Zepbound. Zepbound® is a trademark of Eli Lilly and Company, not affiliated with Zepym Health.
Who is eligible for GLP-1 weight loss treatment?
Generally adults with a BMI of 30 or more, or 27 or more with a weight-related condition. A physician reviews your history before anything is prescribed. GLP-1s are not for people with a personal or family history of medullary thyroid cancer or MEN 2, or during pregnancy.
Semaglutide or tirzepatide?
Semaglutide acts on GLP-1; tirzepatide acts on GLP-1 and GIP and produced more weight loss in its trials. Your physician helps you choose based on your goals, your history and how you tolerate the medicine.
Injection or tablet?
Both come as a weekly injection under the skin or as a tablet that dissolves under the tongue once a day. The tablet avoids needles; your physician explains how each one is taken.
If I've taken a GLP-1 before, can I start at the same dose?
Tell your physician which medicine and dose you took and when. They decide the safest starting point for you.
What side effects should I be aware of?
Nausea, diarrhea, vomiting and constipation are the most common, mostly in the first weeks and when the dose goes up. Severe stomach pain needs medical attention right away.
How long until I see results?
Appetite usually quiets within the first weeks. Weight loss builds month by month as the dose steps up; in the trials it continued for more than a year. Results vary.
Is it for both men and women?
Yes. GLP-1 medicines are prescribed to adult men and women who meet the criteria.
How am I billed?
Monthly, every 3 months or every 6 months; longer plans cost less per month. Shipping is free and you can pause or cancel anytime.
Prescription grade health care, from anywhere.
Answer a few questions online. A U.S.-licensed physician reviews them and, if it's right for you, your treatment ships to your door.
- Online physician visits
- Message your care team anytime
- U.S.-licensed physicians
- Free, discreet shipping
| 1 | Once-weekly semaglutide 2.4 mg in adults with overweight or obesity: mean weight change −14.9% vs −2.4% with placebo at 68 weeks.STEP 1. Wilding JPH et al. N Engl J Med, 2021. | STEP 1. Wilding JPH et al. N Engl J Med, 2021. |
| 2 | Tirzepatide once weekly for the treatment of obesity: mean weight change −20.9% with 15 mg at 72 weeks.SURMOUNT-1. Jastreboff AM et al. N Engl J Med, 2022. | SURMOUNT-1. Jastreboff AM et al. N Engl J Med, 2022. |
| 3 | Semaglutide reduced major adverse cardiovascular events by 20% in 17,604 adults with heart disease and overweight or obesity.SELECT. Lincoff AM et al. N Engl J Med, 2023. | SELECT. Lincoff AM et al. N Engl J Med, 2023. |
| 4 | Lifestyle intervention aiming at 7% weight loss reduced the incidence of type 2 diabetes by 58% in people with prediabetes.Diabetes Prevention Program. N Engl J Med, 2002. | Diabetes Prevention Program. N Engl J Med, 2002. |
| 5 | 73.6% of U.S. adults aged 20 and over have overweight or obesity.CDC, NCHS. NHANES 2017–2018. | CDC, NCHS. NHANES 2017–2018. |
| 6 | Overweight and obesity are associated with an increased risk of at least 13 types of cancer.CDC. Cancers Associated with Overweight and Obesity. | CDC. Cancers Associated with Overweight and Obesity. |
Compounded medications are not FDA-approved for safety, efficacy, or quality.